Physician profile
Priya Sai
NPI 1255444329
$5,589.08
in general payments reported to CMS, 2019-2025
32 companies · $959 in 2025
The $959 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $657 · 2021: $535 · 2022: $922 · 2023: $731 · 2024: $1,037 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,248.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $840.98 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $634.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $461.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $349.39 | 2019-2025 | |
| Lilly USA, LLC | $304.96 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $219.89 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $196.74 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $191.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $126.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.10 | 2019-2025 | Jardiance |
| Amgen INC. | $109.13 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $107.40 | 2022-2025 | |
| Amarin Pharma, INC. | $104.04 | 2019-2021 | |
| Astellas Pharma US INC | $75.38 | 2019-2024 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $71.31 | 2019-2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $51.04 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.49 | 2022 | |
| Daiichi Sankyo INC. | $40.88 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.21 | 2019-2021 | |
| Allergan, INC. | $36.62 | 2019-2020 | |
| Dynavax Technologies Corporation | $32.03 | 2022-2023 | Heplisav-B |
| Eisai INC. | $27.65 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $27.18 | 2019 | |
| Abbott Laboratories | $21.75 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $19.90 | 2023 | |
| Sumitomo Pharma America, INC. | $16.58 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $14.05 | 2019 | |
| Esperion Therapeutics, INC. | $13.86 | 2021 | |
| Horizon Therapeutics Plc | $13.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.32 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Sai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.